柏柏林与肠道微生物群相互作用,是对多囊性卵巢综合征的潜在疗法
Ting-Wei Zhu1,2,3, Xue-Lian Li1,2,3
1Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China.
Clinical and experimental pharmacology & physiology
|August 21, 2023
概括
柏柏林 (BBR) 是一种植物性化合物,通过调节肠道微生物群,在治疗多囊性卵巢综合征 (PCOS) 中表现有前途. 这篇评论探讨了BBR的情况.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 内分泌学 在内分泌学.
背景情况:
- 多囊卵巢综合征 (PCOS) 是一种常见的内分泌疾病,与肠道失调有关.
- 柏柏林 (BBR) 是一种异类类化合物,与肠道微生物群有显著的相互作用.
- 肠道微生物群的不平衡与PCOS的发病有关.
研究的目的:
- 在PCOS的背景下,审查柏柏林和肠道微生物群之间的相互作用.
- 检查BBR如何影响肠道细菌结构和代谢物.
- 了解肠道微生物群对BBR生物可用性和有效性的影响.
主要方法:
- 关于柏柏林,肠道微生物群和PCOS的最新研究的文献综述.
- 对详细说明BBR治疗后肠道细菌组成变化的研究进行分析.
- 研究由微生物群影响的代谢变化和BBR生物可用性.
主要成果:
- 柏柏林治疗改变了肠道细菌的结构.
- BBR影响肠道代谢物,可能影响PCOS.
- 肠道微生物群影响柏柏林的吸收和有效性.
结论:
- 柏柏林证明了PCOS的治疗潜力,通过肠道微生物群调节进行调节.
- 了解BBR-肠道微生物群轴对于PCOS治疗策略至关重要.
- 对BBR通过微生物群对PCOS影响机制的进一步研究是有必要的.
相关概念视频
Oogenesis
63.8K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.8K
Drugs for Treatment of Diarrhea-Predominant IBS
212
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
212
Drugs for Treatment of Constipation-Predominant IBS
206
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
206
Irritable Bowel Syndrome I: Introduction
313
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
313
Fungal Phylum Microsporidia
41
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
41
Irritable Bowel Syndrome III: Medical and Nursing Management
240
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
240


